{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:57:33Z","timestamp":1792789053154,"version":"4.5.0"},"reference-count":116,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T00:00:00Z","timestamp":1518048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>The fluorinated ornithine analog \u03b1-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis. The ubiquitous and essential polyamines have many functions, but are primarily important for rapidly proliferating cells. Thus, ODC is potentially a drug target for any disease state where rapid growth is a key process leading to pathology. The compound was originally discovered as an anticancer drug, but its effectiveness was disappointing. However, DFMO was successfully developed to treat African sleeping sickness and is currently one of few clinically used drugs to combat this neglected tropical disease. The other Food and Drug Administration (FDA) approved application for DFMO is as an active ingredient in the hair removal cream Vaniqa. In recent years, renewed interest in DFMO for hyperproliferative diseases has led to increased research and promising preclinical and clinical trials. This review explores the use of DFMO for the treatment of African sleeping sickness and hirsutism, as well as its potential as a chemopreventive and chemotherapeutic agent against colorectal cancer and neuroblastoma.<\/jats:p>","DOI":"10.3390\/medsci6010012","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T12:46:27Z","timestamp":1518180387000},"page":"12","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases"],"prefix":"10.3390","volume":"6","author":[{"given":"Nicole","family":"LoGiudice","sequence":"first","affiliation":[{"name":"Pacific University School of Pharmacy, Hillsboro, OR 97123, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh","family":"Le","sequence":"additional","affiliation":[{"name":"Pacific University School of Pharmacy, Hillsboro, OR 97123, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Abuan","sequence":"additional","affiliation":[{"name":"Pacific University School of Pharmacy, Hillsboro, OR 97123, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Leizorek","sequence":"additional","affiliation":[{"name":"Pacific University School of Pharmacy, Hillsboro, OR 97123, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Roberts","sequence":"additional","affiliation":[{"name":"Pacific University School of Pharmacy, Hillsboro, OR 97123, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,2,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrc1454","article-title":"Polyamines and cancer: Old molecules, new understanding","volume":"4","author":"Gerner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00726-007-0537-9","article-title":"Targeting the polyamine biosynthetic enzymes: A promising approach to therapy of African sleeping sickness, Chagas\u2019 disease, and leishmaniasis","volume":"33","author":"Heby","year":"2007","journal-title":"Amino Acids"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1042\/bst0310415","article-title":"Polyamine biosynthetic enzymes as drug targets in parasitic protozoa","volume":"31","author":"Heby","year":"2003","journal-title":"Biochem. Soc. Trans."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.2174\/1381612823666170601101644","article-title":"Parasite Polyamines as Pharmaceutical Targets","volume":"23","author":"Roberts","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.jmb.2015.06.020","article-title":"Remaining Mysteries of Molecular Biology: The Role of Polyamines in the Cell","volume":"427","author":"Campbell","year":"2015","journal-title":"J. Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.biocel.2009.07.009","article-title":"Modulation of cellular function by polyamines","volume":"42","author":"Igarashi","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_7","first-page":"106","article-title":"Polyamines: New cues in cellular signal transduction","volume":"16","author":"Bachrach","year":"2001","journal-title":"News Physiol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rai, P.R., Somani, R.R., and Kandpile, P.S. (2017). Ornithine Decarboxylase Inhibition: A strategy to combat various diseases. Mini Rev. Med. Chem.","DOI":"10.2174\/1389557517666170927130526"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1600-0625.2010.01111.x","article-title":"Polyamines and hair: A couple in search of perfection","volume":"19","author":"Ramot","year":"2010","journal-title":"Exp. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-4632.2006.01231.x","article-title":"\u03b1-Difluoromethylornithine, a polyamine inhibitor: Its potential role in controlling hair growth and in cancer treatment and chemo-prevention","volume":"45","author":"Smith","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00726-004-0092-6","article-title":"Inhibitors of polyamine metabolism: Review article","volume":"26","author":"Wallace","year":"2004","journal-title":"Amino Acids"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00726-009-0408-7","article-title":"Functional significance of eIF5A and its hypusine modification in eukaryotes","volume":"38","author":"Park","year":"2010","journal-title":"Amino Acids"},{"key":"ref_13","first-page":"945","article-title":"Development of difluoromethylornithine (DFMO) as a chemoprevention agent","volume":"5","author":"Meyskens","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"14529","DOI":"10.1074\/jbc.R500031200","article-title":"Regulation of ornithine decarboxylase","volume":"281","author":"Pegg","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1021\/ja00476a050","article-title":"Catalytic Irreversible Inhibition of Mammalian Ornithine Decarboxylase (E.C.4.1.1.17) by Substrate and Product Analogs","volume":"100","author":"Metcalf","year":"1978","journal-title":"J. Am. Chem. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1042\/bj2410305","article-title":"Decarboxylation of \u03b1-difluoromethylornithine by ornithine decarboxylase","volume":"241","author":"Pegg","year":"1987","journal-title":"Biochem. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1179\/2047773213Y.0000000105","article-title":"A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis","volume":"107","author":"Babokhov","year":"2013","journal-title":"Pathog. Glob. Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1067\/mjd.2001.117853","article-title":"The eflornithine story","volume":"45","author":"Coyne","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ebikeme, C. (2014). The death and life of the resurrection drug. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002910"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1365-4632.2007.03270.x","article-title":"The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism","volume":"46","author":"Jackson","year":"2007","journal-title":"Int. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/156802611795429167","article-title":"State of the art in African trypanosome drug discovery","volume":"11","author":"Jacobs","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-3305-3-15","article-title":"The development of drugs for treatment of sleeping sickness: A historical review","volume":"3","author":"Steverding","year":"2010","journal-title":"Parasit Vectors"},{"key":"ref_23","first-page":"3850","article-title":"Bioavailability study of oral liquid and tablet forms of \u03b1-difluoromethylornithine","volume":"6","author":"Carbone","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1473-3099(02)00321-3","article-title":"Treatment of human African trypanosomiasis\u2014Present situation and needs for research and development","volume":"2","author":"Legros","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/0140-6736(92)92180-N","article-title":"Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness","volume":"340","author":"Milord","year":"1992","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4103\/0378-6323.35752","article-title":"Eflornithine","volume":"73","author":"Jobanputra","year":"2007","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_27","first-page":"972","article-title":"Percutaneous absorption and pharmacokinetics of eflornithine HCl 13.9% cream in women with unwanted facial hair","volume":"41","author":"Malhotra","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Burke, C.A., Dekker, E., Samadder, N.J., Stoffel, E., and Cohen, A. (2016). Efficacy and safety of eflornithine (CPP-1X)\/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): Design and rationale of a randomized, double-blind, Phase III trial. BMC Gastroenterol., 16.","DOI":"10.1186\/s12876-016-0494-4"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/gutjnl-2014-307235","article-title":"An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis","volume":"65","author":"Lynch","year":"2016","journal-title":"Gut"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","article-title":"Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial","volume":"1","author":"Meyskens","year":"2008","journal-title":"Cancer Prev. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1940-6207.CAPR-08-0203","article-title":"Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas","volume":"2","author":"Zell","year":"2009","journal-title":"Cancer Prev. Res."},{"key":"ref_32","first-page":"226","article-title":"Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma","volume":"4","author":"Bassiri","year":"2015","journal-title":"Transl. Pediatr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: A multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/bmj.39485.592674.BE","article-title":"Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: Cohort study","volume":"336","author":"Priotto","year":"2008","journal-title":"BMJ"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1586\/14787210.2014.959496","article-title":"Treatment options for second-stage gambiense human African trypanosomiasis","volume":"12","author":"Eperon","year":"2014","journal-title":"Expert Rev. Antiinfect. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jcb.240450111","article-title":"A novel suicide inhibitor strategy for antiparasitic drug development","volume":"45","author":"Wang","year":"1991","journal-title":"J. Cell. Biochem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/expr.1998.4237","article-title":"Trypanosoma brucei brucei: Characterization of an ODC null bloodstream form mutant and the action of alpha-difluoromethylornithine","volume":"88","author":"Li","year":"1998","journal-title":"Exp. Parasitol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/EC.00047-09","article-title":"RNA interference-mediated silencing of ornithine decarboxylase and spermidine synthase genes in Trypanosoma brucei provides insight into regulation of polyamine biosynthesis","volume":"8","author":"Xiao","year":"2009","journal-title":"Eukaryot. Cell."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1128\/AAC.41.9.1922","article-title":"Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to d,l-\u03b1-difluoromethylornithine","volume":"41","author":"Iten","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1126\/science.6775372","article-title":"Polyamine metabolism: A potential therapeutic target in trypanosomes","volume":"210","author":"Bacchi","year":"1980","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/0035-9203(85)90195-6","article-title":"Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-\u03b1-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial","volume":"79","author":"Schechter","year":"1985","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4269\/ajtmh.1987.37.525","article-title":"Treatment of human late stage gambiense trypanosomiasis with \u03b1-difluoromethylornithine (eflornithine): Efficacy and tolerance in 14 cases in Cote d\u2019Ivoire","volume":"37","author":"Doua","year":"1987","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00034983.1991.11812528","article-title":"Perspectives in research on and control of African trypanosomiasis","volume":"85","author":"Kuzoe","year":"1991","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"ref_44","unstructured":"Bacchi, C.J. (2017, December 27). Progress in Anti-Polyamine Drug Development\/Chemotherapy vs. Protozoan-Caused Diseases: The DFMO Story. Available online: http:\/\/wizard.musc.edu\/dfmostory.pdf."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Yun, O., Priotto, G., Tong, J., Flevaud, L., and Chappuis, F. (2010). NECT is next: Implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000720"},{"key":"ref_46","first-page":"1157","article-title":"In Vivo effect of eflornithine (DFMO) and some related compounds on Leishmania infantum preliminary communication","volume":"44","author":"Gradoni","year":"1989","journal-title":"Farmaco"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1006\/phrs.1993.1138","article-title":"Effect of a bis(benzyl)polyamine analogue, and DL-\u03b1-difluoromethylornithine on parasite suppression and cellular polyamine levels in golden hamster during Leishmania donovani infection","volume":"28","author":"Mukhopadhyay","year":"1993","journal-title":"Pharmacol. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molbiopara.2010.12.004","article-title":"Oral putrescine restores virulence of ornithine decarboxylase-deficient Leishmania donovani in mice","volume":"176","author":"Olenyik","year":"2011","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1128\/IAI.01236-08","article-title":"Leishmania donovani ornithine decarboxylase is indispensable for parasite survival in the mammalian host","volume":"77","author":"Boitz","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-4632.2006.03079.x","article-title":"Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair","volume":"46","author":"Wolf","year":"2007","journal-title":"Int. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(87)91131-7","article-title":"Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness","volume":"2","author":"Pepin","year":"1987","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1001\/archotol.1989.01860340088024","article-title":"An animal model of hearing loss from \u03b1-difluoromethylornithine","volume":"115","author":"Jansen","year":"1989","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0378-5955(90)90143-D","article-title":"Cochlear damage and increased threshold in \u03b1-difluoromethylornithine (DFMO) treated guinea pigs","volume":"46","author":"Salzer","year":"1990","journal-title":"Hear. Res."},{"key":"ref_54","first-page":"3037","article-title":"Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C \u03b5 transgenic mice by \u03b1-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss","volume":"63","author":"Wheeler","year":"2003","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1432-1033.2004.04009.x","article-title":"Genetic approaches to the cellular functions of polyamines in mammals","volume":"271","author":"Janne","year":"2004","journal-title":"Eur. J. Biochem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1747.2001.01330.x","article-title":"Relation of skin polyamines to the hairless phenotype in transgenic mice overexpressing spermidine\/spermine N1-acetyltransferase","volume":"116","author":"Pietila","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/1523-1747.ep12340155","article-title":"Modulation of murine hair follicle function by alterations in ornithine decarboxylase activity","volume":"106","author":"Soler","year":"1996","journal-title":"J. Investig. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2006.09.025","article-title":"A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women","volume":"57","author":"Hamzavi","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_59","first-page":"1281","article-title":"Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-DL-ornithine","volume":"9","author":"Alberts","year":"2000","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_60","first-page":"355","article-title":"Chemopreventive efficacy of topical difluoromethylornithine and\/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry","volume":"31","author":"Bartels","year":"2009","journal-title":"Anal. Quant. Cytol. Histol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-3-642-10858-7_4","article-title":"Targeting polyamines and inflammation for cancer prevention","volume":"188","author":"Babbar","year":"2011","journal-title":"Recent Results Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/1078-0432.CCR-08-2235","article-title":"Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation","volume":"15","author":"Gerner","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_63","first-page":"989","article-title":"A randomized, placebo-controlled trial of low-dose \u03b1-difluoromethylornithine in individuals at risk for colorectal cancer","volume":"7","author":"Love","year":"1998","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/jnci\/90.16.1212","article-title":"Effect of \u03b1-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention","volume":"90","author":"Meyskens","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1042\/bse0460008","article-title":"Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention","volume":"46","author":"Rial","year":"2009","journal-title":"Essays Biochem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1053\/j.gastro.2010.06.005","article-title":"Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"E96","DOI":"10.1002\/mc.22051","article-title":"Polyamines are oncometabolites that regulate the LIN28\/let-7 pathway in colorectal cancer cells","volume":"53","author":"Paz","year":"2014","journal-title":"Mol. Carcinog."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00726-007-0515-2","article-title":"Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention","volume":"33","author":"Gerner","year":"2007","journal-title":"Amino Acids"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/mc.20008","article-title":"The chemopreventive agent \u03b1-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells","volume":"39","author":"Ignatenko","year":"2004","journal-title":"Mol. Carcinog."},{"key":"ref_70","first-page":"63","article-title":"Time-serial Assessment of Drug Combination Interventions in a Mouse Model of Colorectal Carcinogenesis Using Optical Coherence Tomography","volume":"8","author":"Rice","year":"2015","journal-title":"Cancer Growth Metastasis"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpba.2015.03.001","article-title":"Metabolomics of adherent mammalian cells by capillary electrophoresis-mass spectrometry: HT-29 cells as case study","volume":"110","author":"Ibanez","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/2159-8290.CD-12-0305","article-title":"Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by \u03b1-difluoromethylornithine","volume":"3","author":"Witherspoon","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/jnci\/86.15.1122","article-title":"Dose de-escalation chemoprevention trial of \u03b1-difluoromethylornithine in patients with colon polyps","volume":"86","author":"Meyskens","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_74","first-page":"1864","article-title":"Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of APC mutant Min mouse adenomas, and selective toxicity against APC mutant embryos","volume":"60","author":"Jacoby","year":"2000","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/carcin\/20.3.425","article-title":"Prevention by aspirin and its combination with \u03b1-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon","volume":"20","author":"Li","year":"1999","journal-title":"Carcinogenesis"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/crc.12.22","article-title":"Chemoprevention in patients with genetic risk of colorectal cancers","volume":"1","author":"Laukaitis","year":"2012","journal-title":"Colorectal Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/bjc.2013.15","article-title":"Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas","volume":"108","author":"Raj","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/ncponc1221","article-title":"Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: A major clinical advance","volume":"5","author":"Sporn","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7859","DOI":"10.1073\/pnas.1332465100","article-title":"Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene","volume":"100","author":"Martinez","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1158\/1078-0432.CCR-07-4599","article-title":"Members of the, U.C. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention","volume":"14","author":"Hubner","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"37046","DOI":"10.1038\/srep37046","article-title":"Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer","volume":"6","author":"Janakiram","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/1055-9965.1250.13.7","article-title":"Irreversible ototoxicity associated with difluoromethylornithine","volume":"13","author":"Lao","year":"2004","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/archotol.1997.01900120031004","article-title":"\u03b1-difluoromethylornithine ototoxicity. Chemoprevention clinical trial results","volume":"123","author":"Pasic","year":"1997","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fonc.2012.00162","article-title":"Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma","volume":"2","author":"Gamble","year":"2012","journal-title":"Front. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Saulnier Sholler, G.L., Gerner, E.W., Bergendahl, G., MacArthur, R.B., VanderWerff, A., Ashikaga, T., Bond, J.P., Ferguson, W., Roberts, W., and Wada, R.K. (2015). A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed\/Refractory Neuroblastoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127246"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-med-011514-023121","article-title":"Neuroblastoma: Molecular pathogenesis and therapy","volume":"66","author":"Louis","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1158\/1078-0432.CCR-08-3213","article-title":"Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma","volume":"15","author":"Evageliou","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Rasmuson, A., Segerstrom, L., Nethander, M., Finnman, J., Elfman, L.H., Javanmardi, N., Nilsson, S., Johnsen, J.I., Martinsson, T., and Kogner, P. (2012). Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0051297"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1158\/0008-5472.CAN-08-2968","article-title":"Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma","volume":"69","author":"Rounbehler","year":"2009","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"9735","DOI":"10.1158\/0008-5472.CAN-07-6866","article-title":"ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma","volume":"68","author":"Hogarty","year":"2008","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u2018undruggable\u2019 cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/sj.onc.1208808","article-title":"Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells","volume":"24","author":"Wallick","year":"2005","journal-title":"Oncogene"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/1097-0142(19840315)53:6<1294::AID-CNCR2820530612>3.0.CO;2-M","article-title":"Potentiation of methylglyoxal-bis-guanylhydrazone by \u03b1-difluoromethylornithine in rat prostate cancer","volume":"53","author":"Herr","year":"1984","journal-title":"Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1158\/1078-0432.CCR-15-2539","article-title":"Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression","volume":"22","author":"Evageliou","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1042\/bj1920941","article-title":"Intracellular putrescine and spermidine deprivation induces increased uptake of the natural polyamines and methylglyoxal bis(guanylhydrazone)","volume":"192","author":"Seppanen","year":"1980","journal-title":"Biochem. J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/ijc.21621","article-title":"Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma","volume":"118","author":"Chen","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0014-5793(82)80775-8","article-title":"An essential role for polyamines in tumor metastases","volume":"150","author":"Sunkara","year":"1982","journal-title":"FEBS Lett."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1021\/jm801580w","article-title":"Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor","volume":"52","author":"Burns","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e27360","DOI":"10.4161\/onci.27360","article-title":"Polyamine blockade promotes antitumor immunity","volume":"3","author":"Hayes","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/2326-6066.CIR-13-0120-T","article-title":"Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment","volume":"2","author":"Hayes","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1017\/erm.2013.3","article-title":"Polyamines and cancer: Implications for chemotherapy and chemoprevention","volume":"15","author":"Nowotarski","year":"2013","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ijc.28139","article-title":"AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport","volume":"133","author":"Samal","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrd2243","article-title":"Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases","volume":"6","author":"Casero","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"84140","DOI":"10.18632\/oncotarget.20493","article-title":"A novel polyamine blockade therapy activates an anti-tumor immune response","volume":"8","author":"Alexander","year":"2017","journal-title":"Oncotarget"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.pcan.4500420","article-title":"Polyamine depletion therapy in prostate cancer","volume":"3","author":"Devens","year":"2000","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Gitto, S.B., Pandey, V., Oyer, J.L., Copik, A.J., Hogan, F.C., Phanstiel, O., and Altomare, D.A. (2018). Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer. Mol. Pharm.","DOI":"10.1021\/acs.molpharmaceut.7b00718"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1021\/jm401174a","article-title":"Polyamine transport inhibitors: Design, synthesis, and combination therapies with difluoromethylornithine","volume":"57","author":"Muth","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Massaro, C., Thomas, J., and Phanstiel Iv, O. (2017). Investigation of Polyamine Metabolism and Homeostasis in Pancreatic Cancers. Med. Sci., 5.","DOI":"10.3390\/medsci5040032"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Phanstiel, O. (2017). An overview of polyamine metabolism in pancreatic ductal adenocarcinoma. Int. J. Cancer.","DOI":"10.1002\/ijc.31155"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1158\/1940-6207.CAPR-14-0176","article-title":"Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling","volume":"7","author":"Mohammed","year":"2014","journal-title":"Cancer Prev. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1940-6207.CAPR-09-0096","article-title":"A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of \u03b1-difluoromethylornithine in subjects with previous history of skin cancer","volume":"3","author":"Bailey","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1940-6207.CAPR-12-0429","article-title":"Difluoromethylornithine: The proof is in the polyamines","volume":"5","author":"Jeter","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1940-6207.CAPR-12-0233","article-title":"A phase III skin cancer chemoprevention study of DFMO: Long-term follow-up of skin cancer events and toxicity","volume":"5","author":"Kreul","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Kim, H.I., Schultz, C.R., Buras, A.L., Friedman, E., Fedorko, A., Seamon, L., Chandramouli, G.V.R., Maxwell, G.L., Bachmann, A.S., and Risinger, J.I. (2017). Ornithine decarboxylase as a therapeutic target for endometrial cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0189044"},{"key":"ref_115","first-page":"1323","article-title":"Inhibition of ornithine decarboxylase alters the roscovitine-induced mitochondrial-mediated apoptosis in MCF-7 breast cancer cells","volume":"5","author":"Arisan","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-012-2235-x","article-title":"Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells","volume":"136","author":"Zhu","year":"2012","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/6\/1\/12\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:54:20Z","timestamp":1760194460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/6\/1\/12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,8]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["medsci6010012"],"URL":"https:\/\/doi.org\/10.3390\/medsci6010012","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,8]]}}}